You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

follicular lymphoma grade 3B

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lentiviral-based Gene-edited Immune Cell Therapy

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • Pell's lentiviral-based gene-edited immune cell therapy
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022

Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • CD19-targeted chimeric antigen receptor T-cell
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma Trial in Saint Louis (Mosunetuzumab,

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 14, 2022

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Washington, District of Columbia
  • +6 more
Feb 2, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)

Recruiting
  • B Cell Lymphoma
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 3, 2023

Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

Available
  • Large B-cell Lymphoma
  • +4 more
  • Epcoritamab
  • (no location specified)
Feb 16, 2023

B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL Trial in Stanford (Fludarabine, Cyclophosphamide, CD22 CAR)

Recruiting
  • B-ALL
  • +3 more
  • Stanford, California
    Stanford Medical Center
Jan 14, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +23 more
  • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
Jun 27, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022